A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects

PURPOSE: TPN171H is a novel, potent and selective phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH). The objective of this study was to evaluate the safety, tolerability, and pharmacokinetics of TPN171H in healthy subjects after single and multiple...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Hongjie, Chen, Qian, Liang, Liyu, Zou, Yang, Pu, Huahua, Xin, Liang, Song, Rong, Li, Tingting, Zhu, Huijuan, Wang, Yu, Tian, Guanghui, Shen, Jingshan, Jiang, Hualiang, Yu, Chen, Wang, Zhen, Jia, Jingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273902/
https://www.ncbi.nlm.nih.gov/pubmed/34262260
http://dx.doi.org/10.2147/DDDT.S308610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273902/
https://www.ncbi.nlm.nih.gov/pubmed/34262260
http://dx.doi.org/10.2147/DDDT.S308610

Ejemplares similares